Phase 3 N=363 LACunar Intervention (LACI-2) Trial-2
Cerebral Small Vessel Diseases · Stroke, Lacunar
Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Scleroderma
Primary: Proportion of Patients Improving Their EndoPAT Reactive Hyperemia Index (RHI) at the End-of-study (16 Weeks) — 6; 4 Participants
N/A N=10 Correlating Brain Tissue Oxygen and Regional Cerebral Oximetry
Stroke
Primary: Correlation Between Regional Cerebral Oximetry (RSO2) and Cerebral Oxygen Tissue Tension (PbrO2). — .5 Spearman Correlation (rs) Coefficient — p=0.036
N/A N=10 Microembolic Signals and Cerebrospinal Fluid Markers of Neuronal Damage After Surgical Aortic Valve Replacement
Aortic Stenosis
Primary: Transcranial Doppler(TCD) Microembolic Signals During Surgical Aortic Valve Replacement Surgery — 354 units on a scale
N/A N=27 Effects of Pediatric Aquatic Therapy in Children With Spastic Cerebral Palsy
Spastic Cerebral Palsy
Primary: Unit on Gross Motor Function Measure Scale (GMFM) — 5.12; 2.00 units on a scale — p=0.007
Phase 4 N=124 Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis
Cerebral Atherosclerosis
Primary: Change in Mean Value of Lipoprotein Resistance to LPO. — 42.4; 42.9; 55.6; 49.4 seconds — p=0.007
N/A N=8 A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen
Sickle Cell Disease · Thalassemia · Hemoglobinopathies
Primary: Development of GVHD Within 1 Year of BMT — 2 participants
Phase 2 N=11 A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride
Orthostatic Hypotension · Spinal Cord Injury
Primary: Systolic Blood Pressure — 98; 97; 102; 87 mmHg
Phase 2 N=30 The Efficient Brain Study
Metabolism - Cerebral Energy
Primary: Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue — .011; .007; .009; .006 Difference in metabolite amplitude
Phase 2 N=17 A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease
Endothelial Dysfunction
Primary: 6-week Change in Diameter and Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy — 4.6; 4.7; 0.1; 0.2 mm — p=<0.05
N/A N=198 A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Acute Ischemic Stroke From Large Vessel Occlusion
Primary: Number of Participants With Angiographic Revascularization of the Occluded Target Vessel — 82; 79 Participants
N/A N=75 Silk Road Medical First in Man Study - Neuroprotection During Carotid Stenting and Angioplasty
Carotid Artery Diseases
Primary: Safety Evaluation as Composite of Occurrences of Major Stroke, Myocardial Infarction and Death — 0; 0; 0 Occurences
N/A N=34 Cerebral Blood Flow and Childhood Obstructive Sleep Apnea
Obstructive Sleep Apnea Syndrome
Primary: Change in Cerebral Blood Flow (CBF) at Baseline Between Obstructive Sleep Apnea Syndrome (OSAS) and Controls — 184; 209 percentage of change from baseline
N/A N=24 Nebulised Hypertonic Saline in Children and Young People With Neuromuscular Disease and Cerebral Palsy
Neuromuscular Diseases
Primary: Change in Antibiotic Courses — 4; 1; 2.50; 1.00 Courses of antibiotics — p=<0.001
N/A N=74 UTLight-transcranial Doppler Assessment of Regional Cerebral Autoregulation
Diabetes
Primary: To Compare Profiles of TCD-blood Flow Velocities (TCD_BFV). — 28.23; 33.11 cm/sec